38 Fulton St W Ste 303
28 articles about Tetra Therapeutics
Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome
Tetra Therapeutics, a Shionogi Group Company, focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, today announced the initiation of three Phase 2b/3 clinical studies of the investigational drug BPN14770 (zatolmilast) as a potential treatment for Fragile X Syndrome (FXS), the most common genetic form of autism.
Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession
Tetra Therapeutics announced changes to its executive team as the company marks one year since the close of its merger with Shionogi & Co., Ltd..
An investigational Alzheimer's disease drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.
Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome
Study shows significant cognitive improvement in domains related to language and caregivers reported improved language and daily functioning Lead drug candidate continues to be safe and well-tolerated
Tetra Therapeutics today announced that it has entered into a definitive merger agreement for Shionogi & Co., Ltd. to acquire Tetra. With this acquisition, Shionogi will obtain global rights to Tetra’s entire portfolio of compounds for
Tetra Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for patients with cognitive impairment and memory loss, today announced it has entered into an expanded strategic alliance with Shionogi
12/9/2019It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Tetra Therapeutics Announces Presentation of Data from Retrospective Population-Based Study of 56 Million Patients at the 12th Clinical Trials on Alzheimer’s Disease Meeting (CTAD)
Study Shows that TNF Blocking Agents Reduce Risk of Alzheimer’s Disease in Patients with Rheumatoid Arthritis or Psoriasis
Tetra Therapeutics Sees Rapid Patient Recruitment and Representative Patient Diversity in its PICASSO Phase 2 Alzheimer’s Disease Trial
Just ahead of World Alzheimer’s Day on September 21st, Tetra Therapeutics, a clinical-stage biotechnology company, today announced it has surpassed 50% enrollment – 65% of which are Hispanic patients– in its Phase 2 clinical trial (PICASSO AD) of BPN14770 in patients diagnosed with early Alzheimer’s disease (AD), since the trial’s initiation in May.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the company’s name change to Tetra Therapeutics
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization
Deal Valued at Potential $160 Million plus Royalties, including $5 Million in Upfront Payments and $35 Million in Equity Investment
Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent
The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia.
Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome
Tetra’s fragile X syndrome drug must demonstrate significant therapeutic benefits to secure market share, says GlobalData
BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the FDA in April 2018.
FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile X Syndrome
BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype.
Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders.
Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome
Tetra Discovery Partners Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770.
New Preclinical Research Suggests Utility of Tetra Discovery Partners' BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome
Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology.
Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition
BPN14770 is a highly selective inhibitor of PDE4D, which regulates brain signaling pathways involved in the early and late stages of memory formation.